Genenta Science (NASDAQ:GNTA) Trading Up 2.4% – Here’s Why

Genenta Science S.p.A. (NASDAQ:GNTA) traded up 2.4% during mid-day trading on Thursday . The stock traded as high as $5.30 and last traded at $5.30. 966 shares traded hands during trading, a decline of 90% from the average session volume of 9,819 shares. The stock had previously closed at $5.18.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of Genenta Science in a report on Wednesday, October 2nd.

Genenta Science Stock Down 3.2 %

The company has a fifty day simple moving average of $5.22 and a 200-day simple moving average of $4.30.

Institutional Investors Weigh In On Genenta Science

An institutional investor recently bought a new position in Genenta Science stock. AlTi Global Inc. purchased a new stake in shares of Genenta Science S.p.A. (NASDAQ:GNTA) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 200,288 shares of the company’s stock, valued at approximately $621,000. AlTi Global Inc. owned 1.10% of Genenta Science as of its most recent filing with the SEC. Hedge funds and other institutional investors own 15.13% of the company’s stock.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.